• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Viatris Inc.

    6/12/26 4:10:32 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    FWP 1 ny20068251x2_fwp.htm FWP
    Filed Pursuant to Rule 433
    Registration Statement 333-287087

    VIATRIS INC.

    Pricing Term Sheet

    €650,000,000 4.250% Senior Notes due 2033

    June 12, 2026

    This Pricing Term Sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement dated June 12, 2026 relating to the Viatris Inc. notes described below (the “Preliminary Prospectus Supplement”). The information in this Pricing Term Sheet supplements the Preliminary Prospectus Supplement and supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement. Capitalized terms not otherwise defined herein have the meanings ascribed to them in the Preliminary Prospectus Supplement.

    Issuer:
    Viatris Inc.
       
    Guarantors:
    Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
       
    Offering Format:
    SEC Registered
       
    Trade Date:
    June 12, 2026
       
    Settlement Date:
    June 17, 2026 (T+3)
       
    Security Title:
    4.250% Senior Notes due 2033
       
    Principal Amount:
    €650,000,000
       
    Coupon:
    4.250%
       
    Maturity Date:
    June 17, 2033
       
    Public Offering Price:
    99.739% of the principal amount, plus accrued interest, if any, from June 17, 2026
       
    Spread to Mid-Swap:
    +135 bps
       
    Mid-Swap Rate:
    2.944%


    Yield to Maturity:
    4.294%
       
    Benchmark Security:
    2.300% DBR due February 15, 2033
       
    Spread to Benchmark Security:
    +145.3 bps
       
    Benchmark Security Price:
    96.750%
       
    Benchmark Security Yield:
    2.841%
       
    Expected Ratings*:
    Baa3 (Moody’s) / BBB (Fitch) / BB+ (S&P unsolicited)
       
    Interest Payment Date:
    Annually on June 17 of each year, commencing on June 17, 2027
       
    Optional Redemption:
    Prior to April 17, 2033 (the date that is two months prior to the maturity date of the Notes) (the “Par Call Date”), the Issuer may redeem the Notes at its option, in whole or in part, at any time and from time to time, at a Redemption Price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
     
    (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the Redemption Date on an annual basis (ACTUAL/ACTUAL (ICMA)) at the applicable Comparable Government Bond Rate plus 25 basis points, and
     
    (b) 100% of the principal amount of the Notes to be redeemed,
     
    plus, in either case, accrued and unpaid interest thereon to the Redemption Date.
     
    On or after the Par Call Date, the Issuer may redeem the Notes at its option, in whole or in part, at any time and from time to time, at a Redemption Price equal to 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest thereon to the Redemption Date.
       
    Redemption of Notes for Tax Reasons:
    The Issuer may redeem all but not part of the Notes in the event of certain changes in the tax laws of the United States that would require us to pay additional amounts as described under “Description of Notes — Payment of Additional Amounts” at 100% of the principal amount of the Notes, plus accrued and unpaid interest to, but excluding, the date fixed for redemption.

    2

    Change of Control Repurchase Event:
    101% of principal amount plus accrued and unpaid interest thereon, if any, to, but excluding, the repurchase date.
       
    Clearing:
    Global notes will be deposited with a common depositary for Euroclear Bank SA/NV, Belgium and Clearstream Banking S.A., Luxembourg.
       
    Expected Listing:
    Application has been made for the Notes to be admitted to the Official List of Euronext Dublin and to trade on the Global Exchange Market, which is the exchange regulated market of Euronext Dublin.
       
    Governing Law:
    State of New York
       
    Day Count Convention:
    ACTUAL/ACTUAL (ICMA)
       
    Denominations:
    €100,000 and integral multiples of €1,000 in excess thereof
       
    Stabilization:
    FCA / ICMA
       
    Expected Settlement Date:
    It is expected that delivery of the Notes will be made against payment therefor on or about June 17, 2026, which will be the third business day following the date of pricing of the notes (such settlement cycle being herein referred to as “T+3”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes prior to one business day preceding the closing date will be required, by virtue of the fact that the notes initially will settle T+3, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of notes who wish to trade notes prior to one business day preceding the closing date should consult their own advisor.
       
    ISIN / Common Code:
    XS3325429580 / 332542958

    3

    Prohibition of Sales to EEA/UK Retail Investors:
    Applicable
       
    MiFID II/UK MiFIR Target Market:
    No EU PRIIPs key information document (KID) and no UK disclosure document required by DISC have been prepared as the notes are not available to retail in EEA or UK.
       
    Active Joint Book-Running Managers:
    BNP PARIBAS
    Citigroup Global Markets Limited
    Goldman Sachs & Co. LLC
       
    Passive Joint Book-Running Managers:
    Barclays Bank PLC
    Deutsche Bank AG, London Branch
    DNB Bank ASA
       
    Co-Managers:
    ING Bank N.V., Belgian Branch
    J.P. Morgan Securities plc
    Merrill Lynch International
    Mizuho International plc
    Morgan Stanley & Co. International plc
    PNC Capital Markets LLC
    SMBC Bank International plc
    Scotiabank (Ireland) Designated Activity Company
    Société Générale
    Standard Chartered Bank
    Academy Securities, Inc.
    R. Seelaus & Co., LLC
    ------------------------------------

    *A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal by the assigning rating organization at any time. Each rating should be evaluated independently of any other rating.

    The Issuer has filed an automatic shelf registration statement (including a prospectus) and a prospectus supplement with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus and prospectus supplement if you request it by calling (i) BNP PARIBAS at +44 0-20-7595-8222; (ii) Citigroup Global Markets Limited toll-free at +1-800-831-9146 or (iii) Goldman Sachs & Co. LLC toll-free at +1-866-471-2526.

    Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email system.

    4
    Get the next $VTRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    2/9/2026$18.00Neutral → Buy
    UBS
    1/16/2026$15.00Hold → Buy
    Argus
    12/9/2025$15.00Overweight
    Barclays
    10/15/2025$15.00Buy
    Truist
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris upgraded by Argus with a new price target

    Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00

    1/16/26 8:41:55 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Viatris with a new price target

    Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:55:06 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    SEC Filings

    View All

    Viatris Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Viatris Inc (0001792044) (Filer)

    6/18/26 4:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Viatris Inc (0001792044) (Filer)

    6/15/26 4:32:33 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Viatris Inc.

    FWP - Viatris Inc (0001792044) (Subject)

    6/12/26 4:10:32 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Smith Scott Andrew bought $219,740 worth of shares (22,000 units at $9.99), increasing direct ownership by 8% to 314,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    8/13/25 6:08:30 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    5/14/25 6:00:11 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    10/25/24 4:30:03 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

    ETOBICOKE, ON, June 16, 2026 /CNW/ -- Viatris Inc. (NASDAQ:VTRS) has been recognized as one of the 2026 Best Workplaces™ in Canada by Great Place to Work®. This recognition highlights Viatris' commitment to fostering a culture where colleagues feel valued, engaged, and empowered to do meaningful work while making a positive impact on patients and communities.Great Place to Work® is the global authority on workplace culture, employee experience and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. This recognition is the result of an independent evaluation, which uses a rigorous two-step process that includes an anonymous survey to

    6/16/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

    FDA PDUFA Goal Date Set for Dec. 27, 2026PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026. Acute pain affects more than 80 million individuals in the United States each year, where opioids remain a commonly used treatment option.1,2 "FDA's acceptance of

    5/18/26 8:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

    PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET.Investors and the general public are invited to listen to the live webcast of the event at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients

    5/7/26 4:30:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Le Goff Corinne

    4 - Viatris Inc (0001792044) (Issuer)

    4/16/26 6:00:28 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Campbell Paul

    4 - Viatris Inc (0001792044) (Issuer)

    3/24/26 6:04:35 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Viatris Inc.

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:54 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Financials

    Live finance-specific insights

    View All

    Viatris Reports First-Quarter 2026 Financial Results

    Delivers Total Revenues of $3.5 Billion, Representing 8% Reported Growth Compared to First Quarter 2025, and U.S. GAAP Net Earnings of $176 Million Total Revenues Were Up 3% Operationally Compared to First Quarter 2025Adjusted EBITDA was $1.0 Billion Up 10% Operationally Compared to First Quarter 2025, Demonstrating Solid Operating Leverage Progresses Key Launches and Pipeline Milestones Across Multiple Products, Including the Launch of Effexor® for Generalized Anxiety Disorder in JapanContinues to Expect More Than $2.5 Billion of Cash Available for Deployment in 2026Reaffirms 2026 Financial Guidance [1]PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced its fi

    5/7/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Announces Quarterly Dividend

    PITTSBURGH, May 5, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 17, 2026, to shareholders of record as of the close of business on May 22, 2026.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we're developing new medicines, working to maintain a resilient supply of needed

    5/5/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Announces Chief Financial Officer Transition

    Theodora "Doretta" Mistras to Depart; Paul Campbell Named Interim CFOPITTSBURGH, May 4, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Theodora "Doretta" Mistras, Chief Financial Officer, will depart the Company for a new professional opportunity.Viatris has named Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim Chief Financial Officer, effective May 8, 2026, while the Company conducts its search for a permanent successor. Mistras will remain with the Company until May 22, 2026, to facilitate a seamless transition."We thank Doretta for her significant contributions, which have helped prepare the Company

    5/4/26 4:30:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    View All

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

    PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional

    1/8/26 9:05:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

    PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.

    8/19/25 9:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viatris Inc.

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    11/12/24 1:41:20 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    2/13/24 5:17:31 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Viatris Inc.

    SC 13G - Viatris Inc (0001792044) (Subject)

    2/9/24 1:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care